Puma Biotechnology Inc (PBYI)

Nov 04, 2025

Using fundamentals and technicals on Puma Biotechnology Inc.2025 Growth vs Value & Fast Gain Stock Trading Tips - newser.com

Nov 04, 2025

Nov 04, 2025

Using data filters to optimize entry into Puma Biotechnology Inc.Quarterly Portfolio Report & Verified Momentum Stock Watchlist - newser.com

Nov 04, 2025

Nov 03, 2025

Using R and stats models for Puma Biotechnology Inc. forecastingQuarterly Risk Review & Safe Capital Growth Stock Tips - newser.com

Nov 03, 2025

Nov 03, 2025

How strong is Puma Biotechnology Inc. stock revenue growthMarket Performance Report & AI Forecast for Swing Trade Picks - newser.com

Nov 03, 2025

Nov 03, 2025

Using Ichimoku Cloud for Puma Biotechnology Inc. technicalsPortfolio Profit Report & Daily Oversold Bounce Ideas - newser.com

Nov 03, 2025

Nov 03, 2025

How institutional buying supports Puma Biotechnology Inc. stockMarket Activity Report & Daily Oversold Bounce Ideas - newser.com

Nov 03, 2025

Nov 02, 2025

Is Puma Biotechnology Inc. reversing from oversold territoryJuly 2025 Levels & Verified Chart Pattern Trade Signals - newser.com

Nov 02, 2025

Nov 02, 2025

Can Puma Biotechnology Inc. stock withstand economic slowdown2025 Historical Comparison & AI Enhanced Trading Signals - newser.com

Nov 02, 2025

Oct 31, 2025

Global Desmoid Tumors Market Report 2025: Regional and Country-Level Analysis & Forecast to 2035 Featuring SpringWorks Therapeutics, Ayala Pharma, Puma Biotechnology, BMS, Eli Lilly, Ipsen, Deciphera Pharma - Yahoo Finance

Oct 31, 2025

Oct 31, 2025

Puma Biotechnology (PBYI) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Oct 31, 2025

Oct 28, 2025

Will Puma Biotechnology Inc. stock remain a Wall Street favorite - fcp.pa.gov.br

Oct 28, 2025

Oct 27, 2025

Why retail investors favor Puma Biotechnology Inc. stockInflation Watch & Safe Entry Momentum Tips - fcp.pa.gov.br

Oct 27, 2025

Oct 27, 2025

Puma Biotechnology’s Phase 2 Study of Alisertib: A Promising Update for Investors - TipRanks

Oct 27, 2025

Oct 26, 2025

Puma Biotechnology (NASDAQ:PBYI) Downgraded to Hold (C+) Rating by Weiss Ratings - MarketBeat

Oct 26, 2025

Oct 23, 2025

Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2025 Financial Results - BioSpace

Oct 23, 2025

Oct 23, 2025

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results - The AI Journal

Oct 23, 2025

Oct 22, 2025

Puma Biotechnology targets $192M-$198M NERLYNX revenue for 2025 amid strategic efforts - MSN

Oct 22, 2025